J&J 340B Rebate Model – What Covered Entities Need to Know
On August 23, 2024, Johnson & Johnson sent a notice to 340B covered entities announcing a new method for providing 340B discounts on two of their products, STELARA and XARELTO. This new model requires 340B DSH hospitals to upload claims data to a third-party platform and collect the 340B discount as a rebate instead of accessing 340B prices at the point of sale.This proposed model carries significant financial and operational implications for affected covered entities and is likely to face legal challenges. Our expert-led webinar will address the many questions arising from the 340B community regarding this significant change.Event Details - Date: Thursday, September 12, 2024, Time: 1 PM EST / 10 AM PSTMeet Our Expert Speakers• Nick Gnadt, PharmD, 340B ACE, Director of Pharmacy Professional Services, SpendMend• Greg Wilson, PharmD, 340B ACE, Director of Compliance, SpendMendLearning Objectives:• Review the recent J&J policy notice for accessing 340B discounts for STELARA and XARELTO.• Describe the financial, operational, regulatory, and judicial implications of this practice.• Identify strategies and actions that covered entities may want to consider in response to this new practice.SpendMend webinars are offered at no charge to our prospects, clients, and partners.
